Carfilzomib, proteasome inhibitor; intravenous — Competitive Intelligence Brief

Carfilzomib, proteasome inhibitor; intravenous (Carfilzomib, proteasome inhibitor; intravenous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 2 Proteasome inhibitor 20S proteasome Oncology Small molecule

Target snapshot

Carfilzomib, proteasome inhibitor; intravenous (Carfilzomib, proteasome inhibitor; intravenous) — Pfizer. Proteasome inhibitor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carfilzomib, proteasome inhibitor; intravenous TARGET	Carfilzomib, proteasome inhibitor; intravenous	Pfizer	phase 2	Proteasome inhibitor	20S proteasome
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
R2: Lenalidomide + ixazomib maintenance	R2: Lenalidomide + ixazomib maintenance	University of Leeds	phase 3	Immunomodulatory agent + proteasome inhibitor combination	Cereblon (lenalidomide); 20S proteasome (ixazomib)
Bortezomib, Melphalan, Prednisone	Bortezomib, Melphalan, Prednisone	Fondazione EMN Italy Onlus	phase 3	Proteasome inhibitor + alkylating agent + corticosteroid combination	20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone)
VBMCP/VBAD/Velcade	VBMCP/VBAD/Velcade	PETHEMA Foundation	phase 3	Proteasome inhibitor	20S proteasome
TLK286 HCl for injection	TLK286 HCl for injection	Telik	phase 3	Proteasome inhibitor	20S proteasome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class